Activated protein C for severe sepsis: review - PulmCCM
Advertisement
Mar 222011
 

Sadaka et al add their two cents and a cohort study to the Xigris efficacy/safety debate. In their retrospective, propensity-matched analysis of 563 patients sourced from the Project IMPACT database, the 108 who received activated protein C had 35% mortality, vs 54% for the 108 who did not (p=0.005). There were unusually low rates of bleeding (2.8% GI bleeding in APC group, no brain hemorrhages), compared to previous trials of APC. Authors reported no competing interests. Critical Care 2011;15:R89.

Liked this post? Get a weekly email update (no spam, ever), and explore our library of clinical guidelines, practice updatesreview articles. and board review questions.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society or journal referenced on the website.

Leave a Comment